Patent Term Extension Application for RIVFLOZA® (nedosiran), Patent No. 10,351,854

Documents

Comments

Key Dates

Comment Period OpensJan 26, 2024

Comment Period ClosesAug 16, 2025

Type	Title	Posted	Comments	Status
Other	Letter to U.S. Patent and Trademark Office	Apr 20, 2026	--

CDER

Novo Nordisk Health Care AG

Novo Nordisk Inc.

Patent Term Extension Application

for RIVFLOZA® (nedosiran)

Patent No. 10,351,854

OPEN